Inhaled glycopyrronium bromide: A review of its use in patients with moderate to severe chronic obstructive pulmonary disease

Drugs

Volumn 73, Issue 7, 2013, Pages 741-753

  Carter, Natalie J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BREEZHALER; GLYCOPYRRONIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG METABOLISM; DRUG TOLERABILITY; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; REVIEW; TREATMENT DURATION; URINARY TRACT INFECTION; XEROSTOMIA;

ADMINISTRATION, INHALATION; DRUG INTERACTIONS; GLYCOPYRROLATE; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84878632161     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0058-7     Document Type: Review

References (41)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2011. http://www.goldcopd.org/uploads/users/files/GOLD-Report-2011- Feb21.pdf. Accessed 8 Apr 2013.
2. Hudd TR, Zaiken K. Management of chronic obstructive pulmonary disease: an emphasis on recently approved medications and products in the pipeline. Formulary. 2011;46(9):374-93.
3. Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med. 2011;9:7.
4. World Health Organization. World health statistics. 2008. http://www.who.int/whosis/whostat/EN-WHS08-Full.pdf. Accessed 8 Apr 2013.
5. ® (glycopyrronium bromide) powder for inhalation: EU summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002430/WC500133769.pdf. Accessed 8 Apr 2013.
6. Frampton JE. Aclidinium: in chronic obstructive pulmonary disease. Drugs. 2012;72(15):1999-2011.
7. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63:831-8.
8. Agh T, Inotai A, Meszaros A. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011;82:328-34.
9. St Charles M, Blanchette CM, Silver H, et al. Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Curr Med Res Opin. 2010;26(10):2421-9.
10. Rand CS. Patient adherence with COPD therapy. Eur Respir Rev. 2005;14(96):97-101.
11. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(3):371-84.
12. Simoni-Wastila L, Wei Y-J, Qian J, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population. Am J Geriatr Pharmacother. 2012;10(3):201-10.
13. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105:435-41.
14. Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med. 2007;101:1895-902.
15. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J. 2009;34(3):757-69.
16. ® (indacaterol) powder for inhalation: EU summary of product characteristics. 2010. http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/001210/WC500053307.pdf. Accessed 8 Apr 2013.
17. ® (tiotropium bromide monohydrate) powder for inhalation: UK summary of product characteristics. 2012. http://www.medicines.org.uk/EMC/medicine/10039/SPC/ Spiriva+18+microgram+inhalation+powder%2c+hard+capsule/. Accessed 8 Apr 2013.
18. ® (tiotropium bromide monohydrate) solution for inhalation: UK summary of product characteristics. 2012. http://www.medicines.org.uk/EMC/ medicine/20134/SPC/Spiriva+Respimat+2.5+micrograms+solution+for+inhalation/. Accessed 8 Apr 2013.
19. ® 6 (formoterol fumarate dihydrate) powder for inhalation: UK summary of product characteristics. 2010. http://www.medicines.org.uk/EMC/medicine/189/SPC/ Oxis+Turbohaler+6%2c+inhalation+powder/. Accessed 8 Apr 2013.
20. ® 12 (formoterol fumarate dihydrate) powder for inhalation: UK summary of product characteristics. 2010. http://www.medicines.org.uk/EMC/medicine/190/SPC/ Oxis+Turbohaler+12%2c+inhalation+powder/. Accessed 8 Apr 2013.
21. Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012;343(2):520-8.
22. Haddad E-B, Patel H, Keeling JE. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol. 1999;127:413-20.
23. Villetti G, Bergamaschi M, Bassani F, et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol. 2006;148(3):291-8.
24. Casarosa P, Bouyssou T, Germeyer S, et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther. 2009;330(2):660-8.
25. ® (glycopyrronium bromide): European Medicines Agency assessment report. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/002430/WC500133771.pdf. Accessed 8 Apr 2013.
26. Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis. 2012;7:673-8.
27. Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:729-41.
28. Verkindre C, Fukuchi Y, Flémale A, et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010;104(10):1482-9.
29. Sechaud R, Renard D, Zhang-Auberson L, et al. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther. 2012;50(2):118-28.
30. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156.
31. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106-14.
32. Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503-13.
33. Fogarty C, Hattersley H, Di Scala L, et al. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2011;105(3):337-42.
34. Arievich H, Overend T, Renard D, et al. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med. 2012;12:74.
35. Vogelmeier C, Verkindre C, Cheung D, et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010;23(5):438-44.
36. ® (glycopyrronium bromide) powder for inhalation: Canadian prescribing information. 2012.
37. ® as maintenance COPD treatment in the EU. 2012. http://www.novartis.com/newsroom/media-releases/en/2012/ 1645116.shtml. Accessed 8 Apr 2013.
38. Novartis. Novartis QVA149 phase III study meets primary endpoint in reducing exacerbations in COPD patients, filing in EU and Japan by end of year. 2012. http://www.novartis.com/newsroom/media-releases/en/2012/1637183.shtml. Accessed 8 Apr 2013.
39. Novartis. Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149. 2012. http://www.novartis.com/newsroom/media-releases/en/2012/1638207.shtml. Accessed 8 Apr 2013.
40. Novartis. Novartis QVA149 phase III COPD studies meet primary endpoints. 2012. http://www.novartis.com/newsroom/media-releases/en/2012/1599186.shtml. Accessed 8 Apr 2013.
41. The Pharma Letter. Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe. 2012. http://www.thepharmaletter.com/file/117552/ novartisvecturas-qva149-is-filed-as-a-treatment-for-copd-in-europe-certican-eu- approval.html. Accessed 8 Apr 2013.